ILiAD Biotechnologies announces collaboration with Emmes Group on phase 3 pertussis vaccine trial
Betsy Goodfellow | June 25, 2024 | News story | Research and Development | Emmes Group, ILiAD Biotechnologies, Infections and infestations, Vaccine, whooping cough
ILiAD Biotechnologies has announced that it has selected Emmes Group to conduct the upcoming phase 3 trials of its lead pertussis vaccine candidate, BPZE1. The two companies are currently working to finalise a definitive agreement for the collaboration.
The company has selected Emmes Group as its collaborator due to its ‘experience in vaccine development, agility in managing complex clinical trials, strong local market presence, and its integrated technology capabilities’, according to the press release.
Dr Keith Rubin, chief executive officer of ILiAD Biotechnologies, commented: “Selecting Emmes Group for our phase 3 BPZE1 trials has been a carefully considered strategic decision to ensure the highest standards of clinical research. VaxTrials’ specialisation in vaccines and Veridix AI’s advanced technological capabilities will be instrumental in executing our BPZE1 vaccine clinical development plan.”
Sastry Chilukuri, chief executive officer of Emmes Group, added: “We are honoured and pleased that ILiAD has selected Emmes Group as its partner to continue the clinical development of BPZE1. We look forward to working closely with ILiAD’s clinical development team on this promising new vaccine, which could significantly reduce the transmissibility and incidence of Bordetella pertussis, particularly in vulnerable populations.”
Betsy Goodfellow
Related Content
BioNet receives positive EMA opinion on new pertussis vaccine
BioNet has received a positive opinion from the Committee for Medicinal Products for Human Use …
Recipharm offers manufacturing support to vaccine trial from ImmBIO and iiCON
Recipharm, a contract development and manufacturing organisation (CDMO), has successfully manufactured PnuBioVax, a new protein-based …
EMA lifts temporary ban on chikungunya vaccine Ixchiq following safety review
After completing a safety review of Ixchiq – a vaccine for chikungunya – the European …
